TABLE 2.
Psychedelic phenethylamine and tryptamine use by the sample
| Participant characteristic |
n | % within full sample |
% within drug group |
|---|---|---|---|
| 2C | |||
| Any 2C | 25 | 64.1 | — |
| 2C-B | 17 | 43.6 | 68.0 |
| 2C-E | 13 | 33.3 | 52.0 |
| 2C-I | 12 | 30.8 | 48.0 |
| 2C-C | 4 | 10.3 | 16.0 |
| 2C-T2 | 4 | 10.3 | 16.0 |
| 2C-T7 | 3 | 7.7 | 12.0 |
| 2C-B-Fly | 2 | 5.1 | 8.0 |
| 2C-D | 2 | 5.1 | 8.0 |
| 2C-P | 2 | 5.1 | 8.0 |
| 2C-T | 1 | 2.6 | 4.0 |
| 2C, not specified | 1 | 2.6 | 4.0 |
| NBOMe | |||
| Any NBOMe | 15 | 38.5 | — |
| 25I-NBOMe | 10 | 25.6 | 66.7 |
| NBOMe, not specified | 5 | 12.8 | 33.3 |
| 25C-NBOMe | 2 | 5.1 | 13.3 |
| 25B-NBOMe | 1 | 2.6 | 6.7 |
| DOx | |||
| Any DOx | 10 | 25.6 | — |
| DOB | 5 | 12.8 | 50.0 |
| DOC | 4 | 10.3 | 40.0 |
| DOM | 2 | 5.1 | 20.0 |
| DOI | 1 | 2.6 | 10.0 |
| Tryptamines | |||
| Any tryptamine | 18 | 46.2 | — |
| 4-AcO-DMT | 12 | 30.8 | 66.7 |
| 4-HO-MET | 5 | 12.8 | 27.8 |
| 5-MeO-DIPT | 3 | 7.7 | 16.7 |
| 5-MeO-DMT | 3 | 7.7 | 16.7 |
| 5-MeO-MIPT | 3 | 7.7 | 16.7 |
| DPT | 2 | 5.2 | 11.2 |
| 3,4-AcO-DMT | 1 | 2.6 | 5.6 |
| 4-AcO-DIPT | 1 | 2.6 | 5.6 |
| 4-AcO-MET | 1 | 2.6 | 5.6 |
| 4-AcO-MIPT | 1 | 2.6 | 5.6 |
| 4-HO-DPT | 1 | 2.6 | 5.6 |
| 4-HO-MPT | 1 | 2.6 | 5.6 |
| 4-MeO, not specified | 1 | 2.6 | 5.6 |
| 5-MeO-AMT | 1 | 2.6 | 5.6 |
| 5-MeO-DOT | 1 | 2.6 | 5.6 |
| 5-MeO-MIT | 1 | 2.6 | 5.6 |
| AMT | 1 | 2.6 | 5.6 |